XML 77 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation, Stock Options, Activity
A summary of the Company’s stock option activity and related information is as follows:
Options Outstanding
Shares
Available for Grant 
Shares Subject to Options OutstandingWeighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Years)Aggregate Intrinsic Value
(unaudited)
(in thousands)
Balance as of January 1, 2025
11,996,2644,631,750$32.98 7.1$35,980 
2018 Plan annual increase(1)
3,689,000
Granted(524,770)524,77043.07 
Exercised(44,121)17.39 
Canceled— 
Restricted stock units granted
(2,101,246)— 
Restricted stock units canceled
372,571— 
Performance-based restricted stock units granted(281,378)— 
Performance-based restricted stock units adjusted for performance achievement(144,972)— 
Performance-based restricted stock units canceled178,807— 
Balance as of March 31, 2025
13,184,2765,112,399$34.15 7.2$75,088 
Vested and Exercisable as of March 31, 2025
2,583,531$34.40 5.2$49,952 
(1)Effective as of January 1, 2025, an additional 3,689,000 shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.
Schedule of Restricted Stock Activity
A summary of the Company’s restricted stock unit activity excluding the performance-based restricted stock units and related information is as follows:
Restricted Stock Units OutstandingWeighted-Average Grant Date Fair Value
(unaudited)
Balance as of January 1, 2025
7,020,251$30.11 
Granted2,101,24643.06 
Vested and released(318,900)30.31 
Canceled(372,571)30.01 
Balance as of March 31, 2025
8,430,026$33.34 
A summary of the Company’s PSU activity and related information is as follows:
Performance-based Restricted Stock Units OutstandingWeighted-Average Grant Date Fair Value
(unaudited)
Balance as of January 1, 2025
1,290,684$37.07 
Granted281,37843.10 
Vested and released(266,490)69.81 
Adjusted for performance achievement144,97219.29 
Canceled(178,807)63.34 
Balance as of March 31, 2025
1,271,737$25.69 
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan
The following table presents the effect of employee and non-employee related stock-based compensation expense:
Three Months Ended March 31,
20252024
(unaudited)
(in thousands)
Cost of revenue
$2,286 $1,756 
Research and development expense
12,527 9,932 
Sales and marketing expense
9,831 7,256 
General and administrative expense
13,113 8,097 
Total stock-based compensation expense
$37,757 $27,041 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:
Three Months Ended March 31,
20252024
(unaudited)
Expected term (in years)
5.80 - 5.90
5.72
Expected volatility
65.7% - 66.1%
69.3%
Risk-free interest rate
4.2% - 4.3%
4.3%
Expected dividend yield
—%
—%